|
|
|
|
||
Re: Roth Capital Maintains Buy on Galena Biopharma; Sees 325% UpsideGALE seems to have a decent strategy of using low risk, modest revenue-producing assets that wouldn't get the attention of bigger pharma companies (Abstral, Zuplenz) to help fund high-risk assets with blockbuster potential (NeuVax, GALE-301, GALE-401). Having the revenue-producing assets certainly puts GALE on a more solid financial footing while the higher-value assets are developed. |
return to message board, top of board |